Prabhu Aruna, Mishra Deepti, Brandl Andreas, Yonemura Yutaka
Department of Surgical Oncology, Thangam Cancer Center, Namakkal, India.
Digestive Unit, Champalimaud Foundation, Lisbon, Portugal.
Front Oncol. 2022 May 26;12:864647. doi: 10.3389/fonc.2022.864647. eCollection 2022.
The treatment of patients with peritoneal metastasis from gastric cancer continues to evolve. With various forms of intraperitoneal drug delivery available, it is now possible to reach the sites of peritoneal metastases, which were otherwise sub-optimally covered by systemic chemotherapy, owing to the blood peritoneal barrier. We conducted a narrative review based on an extensive literature research, highlighting the current available intraperitoneal treatment options, which resulted in improved survival in well-selected patients of peritoneally metastasized gastric cancer. Intraperitoneal chemotherapy showed promising results in four different treatment modalities: prophylactic, neoadjuvant, adjuvant, and palliative. It is now possible to choose the type of intraperitoneal treatment/s in combination with systemic treatment/s, depending on patients' general condition and peritoneal disease burden, thus providing individualized treatment to these patients. Randomized controlled trials for the different treatment modalities were mainly conducted in Asia and lack further validation in the other parts of the world. Most recent application tools, such as pressurized intraperitoneal aerosol chemotherapy, seem promising and need to pass the ongoing clinical trials.
胃癌腹膜转移患者的治疗方法不断发展。由于有多种形式的腹腔内给药方式,现在能够到达腹膜转移部位,而这些部位由于血腹屏障,以往在全身化疗中未能得到最佳覆盖。我们基于广泛的文献研究进行了一项叙述性综述,重点介绍了当前可用的腹腔内治疗选择,这些选择使精心挑选的腹膜转移胃癌患者的生存率得到了提高。腹腔内化疗在四种不同的治疗模式中显示出了有前景的结果:预防性、新辅助性、辅助性和姑息性。现在可以根据患者的一般状况和腹膜疾病负担,选择腹腔内治疗类型与全身治疗相结合的方式,从而为这些患者提供个体化治疗。针对不同治疗模式的随机对照试验主要在亚洲进行,在世界其他地区缺乏进一步验证。最新的应用工具,如加压腹腔内气溶胶化疗,似乎很有前景,需要通过正在进行的临床试验。